Ebastine after surgery for liver cancer
Part of Cancer clinical trials.
This trial tests whether taking the allergy medication ebastine after liver cancer surgery can help prevent the cancer from coming back. It is specifically for people whose tumors show a pattern called 'tumor budding,' which may indicate a higher risk of spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of liver cancer called hepatocellular carcinoma that has not spread to other parts of the body.
- Your tumor shows a specific pattern called 'tumor budding' (seen under a microscope).
- You are expected to live at least 3 more months.
- You have not had any prior cancer treatment (like chemotherapy, radiation, targeted therapy, or immunotherapy) before your surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
This study looks at whether giving additional treatment after surgery helps people with a certain type of liver cancer (hepatocellular carcinoma) that shows tumor budding. Tumor budding is a lab finding that may indicate a higher chance of the cancer coming back.
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
Hear when a new Hepato Cellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.